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Objective: We report on our early experience in living-donor lobar lung transplan-
tation for patients with various lung diseases including restrictive, obstructive,
septic, and hypertensive lung diseases.
Methods: From October 1998 to March 2002, living-donor lobar lung transplanta-
tion was performed in 14 patients with end-stage lung diseases. There were 11
female patients and 3 male patients, with ages ranging from 8 to 53 years, including
4 children and 10 adults. Diagnoses included primary pulmonary hypertension (n 
6), idiopathic interstitial pneumonia (n  2), bronchiolitis obliterans (n  2),
bronchiectasis (n 2), lymphangioleiomyomatosis (n 1), and cystic fibrosis (n
1). Bilateral living-donor lobar lung transplantation was performed in 13 patients
and right single living-donor lobar lung transplantation was performed for a 10-
year-old boy with primary pulmonary hypertension.
Results: All the 14 patients are currently alive with a follow-up period of 4 to 45
months. Although their forced vital capacity (1327  78 mL, 50.2% of predicted)
was limited at discharge, arterial oxygen tension on room air (98.5  1.8 mm Hg)
and systolic pulmonary artery pressure (24.8  1.6 mm Hg) were excellent. Forced
vital capacity improved gradually and reached 1894  99 mL, 67.4% of predicted,
at 1 year. All donors have returned to their previous lifestyles.
Conclusions: Living-donor lobar lung transplantation can be applied to restrictive,
obstructive, septic, and hypertensive lung diseases. This type of procedure can be an
alternative to conventional cadaveric lung transplantation for both pediatric and
adult patients who would die soon otherwise.
Living-donor lobar lung transplantation (LDLLT) was developed byDr Starnes and his colleagues with satisfactory intermediate survivaland functional results.1 Their excellent works encouraged us to applythe operation to critically ill patients with a wide rage of pathophys-iology at Okayama University Hospital in Japan. We report on ourearly experience with our first 14 patients receiving LDLLT.
Methods
Patient and Donor Selection
Patients being considered for LDLLT should meet the criteria for conventional bilateral lung
transplantation. The policy of our program has been to limit LDLLT to critically ill patients
who are unlikely to survive the long wait for cadaveric lungs. Inclusion criteria for donor
were as follows:
Relatives within the second degree or a spouse
20  age  55 years
ABO compatibility
No significant medical history or active medical problems
No recent viral infection
No abnormalities on the echocardiogram
No significant pulmonary pathology on computed tomography on donor side
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Arterial oxygen tension  80 mm Hg
Forced vital capacity, forced expiratory volume in 1 second 
85% of predicted
No previous thoracic operation on donor side
Potential donors were interviewed by 3 physicians with an
observer to safeguard against coercion and to ensure donor com-
prehension of the procedure. The interview was performed at least
3 times to provide potential donors multiple opportunities to ques-
tion, reconsider, or withdraw as a donor. The larger donor was
selected for donation of the right lower lobe.
After multidisciplinary assessment, each case was carefully
discussed by the Lung Transplant Evaluation Committee at
Okayama University Hospital. The members of the committee
consisted of 3 pulmonologists, 3 surgeons, and 1 cardiologist.
Size Matching
Given that the right lower lobe consists of 5 segments, the left
lower lobe of 4, and the whole lung of 19, total forced vital
capacity (FVC) of the 2 grafts was estimated by the following
equation.
Total FVC of the 2 graftsMeasured FVC of the right donor
 5/19Measured FVC of the left donor 4/19
When the total FVC of the 2 grafts was 50% of the predicted
FVC of the recipient (calculated from a knowledge of height, age,
and sex), we accepted the size disparity regardless of the recipi-
ent’s diagnosis.
Donor Technique
Epidural catheters for postoperative analgesia were placed rou-
tinely the day before the surgery to avoid complications related to
heparinization during the donor lobectomies. The recipient and the
right-side donor were brought to the separate operating rooms at
the same time. The left-side donor was brought to the third
operating room 30 minutes later. Three surgical teams were re-
quired and they communicated closely to minimize graft ischemic
time. After induction of general anesthesia, donors were intubated
with a left-sided double lumen endotracheal tube. Fiberoptic bron-
choscopy was performed to determine if lower lobectomy was
feasible, leaving adequate length for closure on the donor bronchus
and length for anastomosis in the recipient.
A detailed description of the technical aspects of the donor
lobectomy has been previously published by Starnes’ group.2
Briefly, the donors were placed in the lateral decubitus position,
and a posterolateral thoracotomy was performed through the fifth
intercostal space. Fissures were developed using linear stapling
devices. The pericardium surrounding the inferior pulmonary vein
was opened circumferentially. Dissection in the fissure was carried
out to isolate the pulmonary artery to the lower lobe and to define
the anatomy of the pulmonary arteries to the middle lobe in the
right side of the donor and to the lingular segment in the left side
of the donor. If the branches of the middle lobe artery and lingular
artery were small, they were ligated and divided. Intravenous
prostaglandin E1 was administered to decrease systolic blood
pressure by 10 to 20 mm Hg. Ten thousand units of heparin and
500 mg of methylprednisolone were administered intravenously.
After placing vascular clamps in appropriate positions, the division
of the pulmonary vein, pulmonary artery, and bronchus were
carried out in this order. Vascular stumps were oversewn with a
5-0 Prolene continuous suture (Ethicon, Tokyo, Japan). The bron-
chial stump was closed with 3-0 Prolene interrupted sutures. Then,
each bronchial closure was covered with a pedicled pericardial fat
tissue. Heparinization was reversed by administering protamine.
On the back table, the lobes were flushed with 1 L of Euro-
Collins solution both antegradely and retrogradely from a bag
about 50 cm above the table. Lobes were gently ventilated with
room air during the flush.
Recipient Technique
Patients were anesthetized and intubated with a single lumen
endotracheal tube in children and with a left-sided double lumen
endotracheal tube in adults. A Swan-Ganz catheter was placed.
Intraoperative transesophageal echocardiography was employed
routinely. The “clamshell” incision was used and the sternum was
transected. The ascending aorta and the right atrium were cannu-
lated and patients were placed on standard cardiopulmonary by-
pass. After bilateral pneumonectomy, the right lower lobe implan-
tation was performed followed by the left lower lobe implantation.
The first implanted right graft was packed in iced saline and slush
while the left graft was implanted. The sequence of the recipient
anastomosis was the bronchus, vein, and artery. The bronchial
anastomosis was begun with a running 4-0 polydioxanone suture
for membranous portion and completed with simple interrupted
sutures for cartilaginous portion. We used end-to-end anastomosis
when the bronchial size was equivalent, and we used telescoping
technique when the discrepancy in bronchial size was obvious. The
bronchial wrapping was not employed except for the patients on
high-dose steroid therapy. Just before completing the bilateral
implantations, 500 mg to 1 g of methylprednisolone was given
intravenously and nitric oxide inhalation was initiated at 20 ppm.
After both lungs were reperfused and ventilated, cardiopulmonary
bypass was removed. At the conclusion of the operation, a nasal
feeding tube was inserted to the proximal jejunum under the
fluoroscope.
Postoperative Management of the Recipient
The patient was kept intubated at a positive end-expiratory pres-
sure of 5 cm H2O for at least 3 days to maintain optimal expansion
of the small lobes implanted. The suction of the chest drainage
tubes started at 10 cm H2O and gradually decreased to water seal
in a couple of days. Fiberoptic bronchoscopy was performed every
12 hours while intubated to assess donor airway viability and to
suction any retained secretions. An intensive program of chest
physiotherapy was given every 4 hours and bedside postoperative
pulmonary rehabilitation was initiated as soon as possible. Post-
operative immunosuppression was a triple-drug therapy consisting
of cyclosporine or tacrolimus, azathioprine or mycophenolate
mofetil, and corticosteroids. Induction therapy with monoclonal or
polyclonal antibodies has not been used. Acute rejection was
clinically judged without transbronchial lung biopsy and treated
with bolus injection of methylprednisolone. Cytomegalovirus pro-
phylaxis with ganciclovir was given to all recipients for the first 3
months.
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Results
Table 1 lists the preoperative data on the 14 patients who
have undergone LDLLT from October 1998 through March
2002. There were 11 female patients and 3 male patients
with ages ranging from 8 to 53 years (average 25.7 years).
Four of the patients were children and 10 were adults. The
height ranged from 122 cm to 160 cm (average 148.9 cm)
and the weight ranged from 20 kg to 55 kg (average 35.8
kg). Body mass index (BMI) ranged from 12.2 kg/m2 to
22.9 kg/m2 (average 15.9 kg/m2). Diagnoses included pri-
mary pulmonary hypertension (n 6), idiopathic interstitial
pneumonia (n  2), bronchiolitis obliterans (n  2, one
after bone marrow transplant and one after Steven-Johnson
syndrome3), bronchiectasis (n  2, one associated with
primary ciliary dyskinesia4), lymphangioleiomyomatosis (n
 1), and cystic fibrosis (n  1). All patients were hospital-
bound and were dependent on continuous oxygen inhala-
tion. Six patients were steroid-dependent. All 6 patients
with primary pulmonary hypertension (PPH) were on high-
dose intravenous epoprostenol (average, 104.5 ng/kg/min)
and inotropic therapy. Two patients (cases 1 and 13) were
ventilator-dependent for 2 and 7 weeks, respectively. Two
other patients were about to be intubated and required a
noninvasive positive pressure ventilator with 100% inspired
oxygen. Five patients received LDLLT on an emergency
basis. Bilateral LDLLT was performed in 13 patients, and
right single LDLLT was performed for a 10-year-old boy
with PPH (case 7),5 because his mother was the only avail-
able donor.
Among the 27 living-donors, 9 were the mothers of
recipients, 6 were fathers, 5 were brothers, 3 were sisters, 2
were daughters, 1 was a son, and 1 was a husband. The
average height and weight of the right-side donor were
168.0 cm and 66.4 kg, and those of the left-side donor were
159.0 cm and 55.8 kg, respectively. The total FVC of the 2
grafts was estimated to be ranging from 51.7% to 103.0%
(average 67.0%) of the predicted FVC of the recipient.
Nine patients received an ABO-identical LDLLT and 5
patients (cases 2, 4, 10, 11, and 12) received LDLLT with a
minor ABO mismatch.
In 6 patients (cases 1, 3, 4, 6, 8, and 9), partial cardio-
pulmonary bypass was initiated using the femoral vessels
under local anesthesia because of their unstable preopera-
tive condition. Then, they were anesthetized and intubated.
Cardiopulmonary bypass was successfully removed from all
14 patients at the end of the procedure. The systolic pul-
monary artery pressure was 38.9 2.0 mm Hg immediately
after the bypass was stopped. The ischemic time of the right
graft was 154 10 minutes, and that of the left graft was 99
 6 minutes.
The operative morbidity of the recipients is depicted in
Table 2. Only 3 (21%) of 14 patients had no complications.
The most frequent complication was lung edema, which
occurred in 5 patients (36%). Tracheostomy was required in
6 patients, reintubation in 5, differential mechanical venti-
lation in 2, rethoracotomy in 2, and extracorporeal mem-
brane oxygenation (ECMO) and continuous hemodiafiltra-
tion in 1. There were no airway complications in the 27
bronchial anastomoses. No infection was encountered. Dur-
ing the first month, acute rejection occurred at an average
rate of 1.4 episodes/patient.
For the 14 recipients, duration of mechanical ventilation
required was 9.5  2.5 days, length of stay in the intensive
care unit was 20.4  3.6 days, and length of hospital stay
was 57.3  5.1 days. Functional assessment before dis-
charge (1 to 3 months after transplantation) is summarized
TABLE 1. Vital data of the 14 patients who underwent living-donor lobar lung transplantation
Case
Age,
sex Diagnosis
Height
(cm)
Weight
(kg)
BMI
(kg/m2)
Date of
operation O2 Steroid Epoprostenol Inotropes Ventilator Emergency Outcome
1 24, F BE (PCD) 153 36.5 15.6 10/28/98     45 months, alive
2 29, F BO (after BMT) 149 32.6 14.7 5/10/00   27 months, alive
3 23, F LAM 148 36 16.4 10/18/00  21 months, alive
4 19, F PPH 157 38 15.4 1/5/01    19 months, alive
5 38, F IIP 155 55 22.9 2/28/01   17 months, alive
6 13, M BO (after SJS) 157 32.3 13.1 3/27/01    16 months, alive
7 10, M PPH 122 20.4 13.6 5/14/01    15 months, alive
8 53, F IIP 159 44 17.4 7/8/01    NIPPV  13 months, alive
9 27, F PPH 160 50.8 19.8 7/23/01     NIPPV  12 months, alive
10 52, F BE 137 35 18.7 8/13/01  12 months, alive
11 8, M PPH 126 20 12.6 11/19/01    8 months, alive
12 13, F PPH 147 29.7 13.4 2/18/02    5 months, alive
13 25, F CF 154 29 12.2 2/25/02     5 months, alive
14 31, F PPH 160 41.7 16.3 3/25/02    4 months, alive
BE, Bronchiectasis; PCD, primary ciliary dyskinesia; BO, bronchiolitis obliterans; BMT, bone marrow transplantation; LAM, lymphangioleiomyomatosis; PPH,
primary pulmonary hypertension; IIP, idiopathic interstitial pneumonia; SJS, Stevens-Johnson syndrome; CF, cystic fibrosis; BMI, body mass index; NIPPV,
noninvasive positive pressure ventilator.
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in Table 3. Although the patients’ FVC (1327  78 mL,
50.2% of predicted) was limited at discharge, arterial oxy-
gen tension on room air (98.5  1.8 mm Hg) and systolic
pulmonary artery pressure (24.8  1.6 mm Hg) were ex-
cellent. FVC improved gradually and reached 1894  99
mL, 67.4% of predicted, at 1 year (Figure 1). The patients’
6-minute walking distance also increased gradually during
the first year (Figure 2). There was 1 recipient (7%) who
developed bronchiolitis obliterans syndrome (BOS) 10
months after transplantation following cytomegalovirus in-
fection (case 5). At the time of final data analysis in August
2002, the mean time from transplant to final analysis for the
14 patients was 15.6 months, ranging from 4 to 45 months.
There has been no mortality during the observation period.
The operative morbidity of the donors is depicted in
Table 4. Two donors developed middle lobe pneumonia
associated with mild bronchial stricture. They were success-
fully treated with antibiotics and did not require bronchial
dilatation. Atrial fibrillation, would infection, cholecystitis,
and hemosputum were also conservatively treated with
symptomatic improvement. One right-side donor required
reconstruction of the middle lobe bronchus after the bron-
chus intermedius was inadvertently divided. One patient
required rethoracotomy due to bleeding from chest wall;
however, none of the patients required transfusion. All
donors have returned to their previous lifestyles during the
observation period.
Discussion
LDLLT is a new and evolving option for patients with
end-stage lung disease. It was developed by Starnes’ group1
as an alternative to cadaveric lung transplantation. Because
only 2 lobes are transplanted, this procedure seems to be
best suited for children and small adults and has been
applied most exclusively to cystic fibrosis. Recently, Star-
nes’ group has expanded indications for LDLLT to include
pediatric patients with PPH, bronchiolitis obliterans, and
adult patients with pulmonary fibrosis.6 Encouraged by Dr
Starnes and his colleagues in California, we began to apply
the procedure to a wider range of pathophysiology both for
pediatric and adult patients.
Cystic fibrosis is a very rare disease in Japan. There were
only 2 patients with cystic fibrosis among approximately
200 lung transplant referrals to Okayama University Hos-
pital. Indications for lung transplant are quite distinct in
Japan.7 PPH, idiopathic interstitial pneumonia, and lym-
phangioleiomyomatosis (LAM) are the most frequent indi-
cations. The number of available cadaveric donors is quite
limited (5 cases/year in the whole country) and, further-
more, brain death is accepted only for those older than 15
years. Under the circumstance, it is clear that the only
realistic option for most of our patients is to receive
LDLLT.
The most frequent indication in this report was PPH (n
6). Although most PPH patients who have sustained im-
provement of their condition with prostacyclin maintain this
response,8 sudden deterioration into life-threatening com-
plications can occur. All 6 patients with PPH were on
high-dose intravenous epoprostenol (average, 104.5 ng/kg/
min) along with inotropic therapy. There were obvious
concerns regarding whether pulmonary hypertension would
develop in 2 lobes receiving a patient’s entire cardiac out-
put. Their systolic pulmonary artery pressure decreased
from 91.7  11.7 mm Hg to 28.3  2.8 mm Hg at dis-
charge, validating the functional capacity of the 2 lobes to
handle the cardiac output of pediatric and adult recipients
with PPH.9 Of note was that right single lobe transplantation
was successfully performed for a 10-year-old boy.5 His
mother’s right lower lobe was estimated to be as big as his
normal right lung. His systolic pulmonary artery pressure
became 32 mm Hg even though the transplanted lobe re-
ceived 77% of the cardiac output at 1 year.
The amount of tolerable size discrepancy between do-
nors and recipients is currently unknown. The use of sig-
nificantly undersized grafts is potentially problematic be-
cause it could result in poor ventilation due to remaining
large dead space. We rely on the ratio between the total
FVC of the 2 grafts to the predicted FVC of the recipient.
When the ratio is greater than 0.5, we accept the size
disparity regardless of the recipient’s diagnosis. In fact, the
LAM patient (case 3) had markedly hyperinflated lungs and
TABLE 3. Predischarge functional data of the 14 recipients
(1 to 3 months)
Mean  SEM Range
FVC (mL) 1327 78 660-1810
%FVC (%) 50.2 0.9 32.3-79.0
PaO2 (mm Hg) 98.5 1.8 83.8-113.8
Systolic PAP (mm Hg) 24.8 1.6 13-37
6-minute walk (m) 302 19 140-390
FVC, Forced vital capacity; PaO2, arterial oxygen tension; PAP, pulmonary
artery pressure; SEM, standard error of the mean.
TABLE 2. Operative complications in the 14 recipients
Complication No. of patients
Lung edema 5 (36%)
Hemorrhage necessitating rethoracotomy 2 (14%)
Cardiac tamponade 2 (14%)
Left peroneal nerve palsy 2 (14%)
Renal failure 2 (14%)
Massive hemoptysis 1 (7%)
Hemolytic anemia 1 (7%)
Kinking of pulmonary artery 1 (7%)
Right phrenic nerve palsy 1 (7%)
Left recurrent nerve palsy 1 (7%)
Decubitus 1 (7%)
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her lung was much larger than her donor’s on chest x-ray. In
case 5, the height of the left-side donor was 6 cm shorter
than that of the recipient. However, none of our patients
experienced any space problems after LDLLT.
All patients in this report had poor preoperative condi-
tions and quite limited life expectancy. It has been well
documented that PPH (n  6), ventilator dependence (n 
2), and BMI  17 (n  10) are risk factors for operative
mortality.10,11 In most cases, patients far from our center
were examined by the first author at the referral hospital.
Five of them were transported on an emergency basis and
underwent transplantation within as early as 40 hours of
arrival.
Various operative complications occurred in 11 of 14
patients (79%), and some of them were unique to LDLLT.
Lung edema was the most common complication, which
occurred in 5 patients (36%). Knowing that the graft isch-
emic time was short in this procedure, the high incidence of
lung edema must be related to the small grafts implanted. Of
note was that 3 PPH patients required reintubation due to
lung edema associated with left ventricular failure on days
5 to 14, soon after they were extubated. This complication
in patients with pulmonary hypertension has been also re-
ported in bilateral lung transplantation.12 Life-threatening
massive hemoptysis was encountered in 1 patient (case 9),
which was successfully treated with ECMO. Bronchoscopic
examination demonstrated normal bronchial healing, and
chest radiography revealed pulmonary hemorrhages in the
right graft. Although the cause of the bleeding was un-
known, it could be related to increased blood flow in the
small grafts implanted. Transient hemolytic anemia oc-
curred in 1 (case 2) of the 5 patients receiving LDLLT with
a minor ABO mismatch. The patient was blood group A and
received lobes from donors with blood group O. Donor-
derived lymphocytes from blood group O lungs produced
anti-A antibody and caused hemolytic anemia between 10 to
21 days after transplantation. She was successfully treated
with transfusion of group O red cells without developing
renal dysfunction.
In spite of poor preoperative condition and high inci-
dence of operative complications, all recipients were sent
home without need for oxygen inhalation. Because only 2
lobes were implanted, pulmonary function test demon-
strated a limited FVC in recipients at discharge (50.2% of
predicted FVC). However, repeated functional assessments
demonstrated a steady improvement in FVC as well as in
6-minute walking distance during the first year as shown in
the figures. To date, 13 of the 14 patients are active with no
restrictions on activities of daily living. One patient with
BOS (case 5) is still able to carry out daily activities but
requires some restrictions. Her forced expiratory volume in
1 second decreased from 1650 mL at 6 months to 1110 mL
at 1 year; thus she was diagnosed as BOS stage Ia. Her
differential ventilation lung scan revealed marked air trap-
ping to the right graft. Of note was that her right graft was
the only one donated from a non–blood-related donor, her
husband, among the 27 lobes in this report. Starnes and
colleagues recently reported that pediatric patients receiving
LDLLT had less BOS than those receiving conventional
transplantation of cadaveric lungs, although the degree of
TABLE 4. Operative complications in the 27 living-donors
Complication
No. of
patients
Middle lobe pneumonia 2 (7%)
Atrial fibrilation 2 (7%)
Wound infection 2 (7%)
Sleeve lower lobectomy 1 (4%)
Hemorrhage necessitating rethoracotomy 1 (4%)
Cholecystitis 1 (4%)
Hemosputum 1 (4%)
Figure 1. Change in forced vital capacity after living-donor lobar
lung transplantation.
Figure 2. Change in 6-minute walking distance after living-donor
lobar lung transplantation.
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antigenic matches or mismatches do not explain these dif-
ferences in BOS incidence.13
There has been a relatively low incidence of donor mor-
bidity in our experience, and all donors have returned to
their previous lifestyles during the observation period.
However, serious complications, such as bronchial fistula
and pulmonary embolism, have been reported.14,15 Because
of the possible serous morbidity associated with donor
lobectomy, our policy has been to limit LDLLT to critically
ill patients who are unable to wait for cadaveric lungs. We
accept only relatives within the second degree or a spouse as
living-donors, although other centers have expanded the
donor indication to extended family members and unrelated
individuals.14,15
Although our experience in LDLLT is still limited in
numbers (n 14) and in observation period (4 to 45
months), the 100% successful rate is very encouraging.
Meticulous perioperative management, including inhaled
nitric oxide, frequent bronchoscopy, an intensive program
of chest physiotherapy, and routine intubation for at least 3
days, is very important. We believe that “small but perfect
graft” is a great advantage in this procedure. We conclude
that LDLLT can be applied to various end-stage lung dis-
eases including restrictive, obstructive, septic, and hyper-
tensive lung diseases both for pediatric and adult patients.
We acknowledge the excellent advice on our patients’ care
obtained from Elbert P. Trulock, MD (Washington University
School of Medicine), and Mark L. Barr, MD (University of South-
ern California).
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